ADMA Biologics (Nasdaq: ADMA) has received FDA approval for its innovative yield enhancement production process, marking a significant milestone for the biopharmaceutical company. The new process demonstrates an ability to increase production yields by approximately 20% from the same starting plasma volume, benefiting both ASCENIV and BIVIGAM products.
As the first U.S. producer of plasma-derived products to achieve this regulatory approval, ADMA expects meaningful acceleration in revenue and earnings trajectory beginning in late 2025 and accelerating into 2026. The company's internal R&D platform continues to advance, with ongoing development of novel pipeline programs including SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.